Fluence Corporation Limited

Fluence Corporation Limited provides water and wastewater treatment, and reuse solutions for the municipal, commercial, and industrial markets worldwide. The company offers NIROBOX for desalination of seawater and brackish water, as well as for the treatment of fresh and wastewater; NIROFLEX systems for desalination, ultrafiltration and multimedia filtration systems, and reverse osmosis systems. It also provides wastewater treatment products, such as Aspiral, a wastewater treatment solution; SUBRE membrane aerated biofilm reactor modules; EcoBox water reuse systems; Tipton packaged wastewater treatment plants; aeration equipment comprising aerators, mixers, and diffusers; and dissolved air flotation systems. In addition, the company offers food and beverage processing and recovery solutions; and waste-to-energy solutions. Further, it provides project finance, Smart Operations data analytics software, and after-sale support services. Fluence Corporation Limited was incorporated in 2007 and is headquartered in White Plains, New York.

Fluence Corporation Limited trades as EMFGF on OTC. The company is classified in Industrials / Industrial - Pollution & Treatment Controls and reports in USD.

The current profile places the business in Industrial - Pollution & Treatment Controls. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $81.12M of revenue and -$9.64M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Fluence Corporation Limited can be compared against peers such as Logistics Development Group plc, flooidCX Corp., Hexagon Purus ASA, Karbon-X Corp., Maritime Launch Services Inc., Pricer AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $80.10M, beta of 0.03, and return on equity of +104.2%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

EMFGF currently shows total debt of $19.32M and beta of 0.03. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.fluencecorp.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.